A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the ...

Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

The findings highlight the need for public-health strategies aimed at mitigating dementia risk and promoting healthy aging across diverse populations, researchers said. “I think ...

Cases of dementia in the U.S. are expected to steadily rise in the coming years, hitting 1 million annual cases by 2060.

The Alzheimer's Accountability and Investment Act (Public Law 118-93), enacted on October 1, 2024, mandates that the National ...

The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...

The finding has implications for all of us, write Harvard physician-researchers Christopher Worsham and Anupam Jena.

In a simulated trial, the Florey Dementia Index achieved mean absolute errors of 1.57 and 0.70 years for predicting mild cognitive impairment and Alzheimer's disease onset, respectively ...

Mild chronic small vessel disease, or cerebral small vessel disease (CSVD), is an umbrella term for a range of conditions ...

MONDAY, Jan. 13, 2025 (HealthDay News) -- Gum disease appears to disrupt brain activity, potentially increasing a person’s risk of cognitive decline. People with gum disease experienced altered ...

Cognitive profiles for early diagnosis of Dementia with Lewy bodies (DLB) have been outlined in a new study, out today in ...